NRSN vs. ICCC, PDSB, DTIL, ATNM, INMB, IMA, CLNN, VRCA, JMAC, and VTVT
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include ImmuCell (ICCC), PDS Biotechnology (PDSB), Precision BioSciences (DTIL), Actinium Pharmaceuticals (ATNM), INmune Bio (INMB), ImageneBio (IMA), Clene (CLNN), Verrica Pharmaceuticals (VRCA), Maxpro Capital Acquisition (JMAC), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.
NeuroSense Therapeutics vs. Its Competitors
NeuroSense Therapeutics (NASDAQ:NRSN) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 5.6% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
NeuroSense Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.
In the previous week, NeuroSense Therapeutics had 4 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.67 beat NeuroSense Therapeutics' score of 0.65 indicating that ImmuCell is being referred to more favorably in the news media.
NeuroSense Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 1,172.73%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe NeuroSense Therapeutics is more favorable than ImmuCell.
ImmuCell has a net margin of 6.23% compared to NeuroSense Therapeutics' net margin of 0.00%. ImmuCell's return on equity of 6.25% beat NeuroSense Therapeutics' return on equity.
ImmuCell has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.
Summary
ImmuCell beats NeuroSense Therapeutics on 9 of the 16 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroSense Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRSN) was last updated on 9/5/2025 by MarketBeat.com Staff
